Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.» Read More
Gilead Sciences is lifting the biotech sector higher in today's trade, reports CNBC's Meg Tirrell.
Biotech finished 2014 up 44 percent. David Seaburg, thinks biotech will outperform the S&P 500 this year, but there could be some suffering mid-year.
IPO momentum should continue into 2015 after an active 2014 when huge offerings hit like "mammoths from the sky," an analyst said.
CNBC's Dominic Chu takes a look at the biggest winners of the market rally and digs into the massive year-end surge for small caps.
Eric Schmidt, Cowen & Company senior analyst, predicts the biotech sector will outperform the S&P 500 next year.
CNBC's Meg Tirrell provides insight to the selloff in biotech stocks after Express Scripts announced it will exclusively cover AbbVie's hepatitis C drug.
Brewing price sensitivity in the sector, compounded with expensive valuations, led to the selloff in U.S. biotech stocks, says Peter Boockvar, Chief Market Analyst at The Lindsey Group.
Express Scripts' decision to drop Gilead's Sovaldi treatment sparked fears that pharmaceutical firms may have to bow to pricing pressure moving forward, says Andrew McDonald, Co-Portfolio Manager at BioShares Funds.
CNBC's Bob Pisani is tracking the action in biotech stocks into the end of the year. CNBC's Bertha Coombs, provides perspective.
After Express Scripts exclusively selected AbbVie over Gilead and JNJ for its hepatitis C drug, CNBC's Meg Tirrell discusses how the news has impacted the entire biotech industry.
Mark Fisher, MBF Clearing Corp. chairman, shares his favorite stock in the biotech space.
CNBC's Jim Cramer and David Faber discuss Express Scripts' selection of AbbVie over Gilead for its hepatitis C drug and what this means for Gilead.
"We're trying to develop treatments that offer new hope or patients battling cancer," says Hans Bishop, Juno Therapeutics CEO, explaining the technology behind Juno.
Because of its anti-coagulant drug, FXI, Mad Money's Jim Cramer thinks Isis Pharmaceuticals can climb much higher.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.
Two stocks you need to watch ahead of San Francisco's 56th ASH hematology conference, with CNBC's Meg Tirrell.
Discussing some of the best stocks in the biotech industry going into 2015, with Michael Yee, RBC Capital Markets.
CNBC's Meg Tirrell provides insight to Biogen Idec's promising early study on its experimental medicine for Alzheimer's disease. Michael Yee, RBC Capital Markets, explains why the stock is headed higher from here.
Biogen's Alzheimer's drug has shown promise in studies, with CNBC's Meg Tirrell.
A Google-backed service to map DNA and identify potential risk factors for some diseases has been launched in the U.K., months after it was banned in the U.S..